Listed

Quest Diagnostics Inc: Form 10-Q for the period ended Jun 30, 2021

Filed with the SEC on Jul 23, 2021 and accepted by EDGAR at Jul 23, 2021, 16:04 ET.

Share

Management's discussion and analysis

As filed, 52,471 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our Company

Diagnostic Information Services

Quest Diagnostics empowers people to take action to improve health outcomes. We use our extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Our diagnostic information services business ("DIS") provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. We provide services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, accountable care organizations ("ACOs"), and direct contract entities ("DCEs"). We offer the broadest access in the United States to diagnostic information services through our nationwide network of laboratories, patient service centers and phlebotomists in physician offices and our connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. We are the world's leading provider of diagnostic information services. We provide interpretive consultation with one of the largest medical and scientific staffs in the industry. Our DIS business makes up greater than 95% of our consolidated net revenues.

We assess our revenue performance for the DIS business based upon, among other factors, volume (measured by test requisitions) and revenue per requisition.

Each requisition accompanies patient specimens, indicating the test(s) to be performed and the party to be billed for the test(s).

Revenue per requisition is impacted by various factors, including, among other items, the impact of fee schedule changes (i.e., unit price), test mix, payer mix, and the number of tests per requisition. Management uses number of requisitions and revenue per requisition data to assist with assessing the growth and performance of the business, including understanding trends affecting number of requisitions, pricing and test mix. Therefore, we believe that information related to changes in these metrics from period to period are useful information for investors as it allows them to assess the performance of the business.

Diagnostic Solutions

In our Diagnostic Solutions ("DS") businesses, which represent the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and healthcare organizations and clinicians. We are the leading provider of risk assessment services for the life insurance industry. In addition, we offer healthcare organizations and clinicians robust information technology solutions.

Second Quarter Highlights

(dollars in millions, except per share data)

Three Months Ended June 30, 2021 2020
Net revenues $2,550 $1,827
DIS revenues $2,474 $1,764
Revenue per requisition change (3.6)% 15.3%
Requisition volume change 45.2% (17.7)%
Organic requisition volume change 40.1% (18.2)%
DS revenues $76 $63
Net income attributable to Quest Diagnostics $631 $185
Diluted earnings per share $4.96 $1.36
Net cash provided by operating activities $460 $355

For further discussion of the year-over-year changes for the three months ended June 30, 2021 compared to the three months ended June 30, 2020, see Results of Operations below.

Impact of COVID - 19

As a novel strain of coronavirus (COVID-19) continues to impact the economy of the United States and other countries around the world, we are committed to being a part of the coordinated public and private sector response to this unprecedented challenge. We have made substantial investments to expand the amount of COVID-19 testing available to the country and are currently capable of performing approximately 300,000 COVID-19 molecular diagnostic tests per day to aid in the diagnosis of COVID-19 and approximately 350,000 COVID-19 antibody tests per day to aid in the detection of immune response. We have been effectively managing challenges in the global supply chain; and, at this point, we have sufficient supplies to conduct our business.

During 2020 and the first half of 2021, our testing volume and revenues were materially impacted by the COVID-19 pandemic.

During January and February 2020, we experienced growth in DIS revenues and volume compared to the prior year period. However, in March 2020, we experienced a material decline in testing volume due to the COVID-19 pandemic. During May and June 2020, we began to experience a recovery in base testing volume (which excludes COVID-19 testing), which continued in the second half of 2020 and the first half of 2021 driven by people returning to the healthcare system as well as contributions from new Professional Laboratory Services offerings. For the first and second quarters of 2021, our base testing volume, excluding volume associated with recent acquisitions, was 2.8% below and 1.9% above our historical first and second quarter of 2019 levels, respectively. Recent agreements associated with our Professional Laboratory Services offerings contributed 5.2% and 5.8% volume growth compared to 2019 for the first and second quarters of 2021, respectively. Unless there is a change in the severity of the COVID-19 pandemic, we believe that there will be a continued return to healthcare throughout 2021 with, in some cases, patients pursuing care delayed during the COVID-19 pandemic.

The decrease in base testing volume was driven by federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home policies, all of which have had, and may continue to have, an impact on our operating results, financial position and cash flows.

Beginning during the second quarter of 2020, we experienced growing demand for COVID-19 testing services and we expanded our capacity throughout 2020 in order to satisfy the demand, which has had a significant impact on our testing volumes. Since the fourth quarter of 2020, demand for COVID-19 testing has decreased reflecting an industry-wide trend. Compared to the fourth quarter of 2020, our net revenues associated with COVID-19 testing in the first and second quarters of 2021 declined by 27.9% and 55.7%, respectively. Given the significant progress of vaccinations in the U.S., we continue to expect a decline in demand for COVID-19 molecular testing in the second half of 2021.

Additionally, our revenue per requisition has been positively impacted by COVID-19 molecular testing. In April 2020 the Centers for Medicare and Medicaid Services ("CMS") announced that it would increase the reimbursement for certain COVID-19 molecular tests making use of high-throughput technologies developed by the private sector that allow for increased testing capacity, faster results, and more effective means of combating the spread of the virus to $100 per test, effective April 14, 2020. Beginning January 1, 2021, Medicare changed the base reimbursement rate for COVID-19 diagnostic tests run on high-throughput technologies to $75 per test with an additional payment of $25 per test if the laboratory (1) completes the test in two calendar days or less and (2) completes the majority of its COVID-19 tests that use high throughput technology in two calendar days or less for all of its patients in the previous month. Certain healthcare insurers have now moved to a similar reimbursement model for COVID-19 molecular tests.

We believe the COVID-19 pandemic’s impact on our consolidated results of operations, financial position and cash flows will be primarily driven by: the severity and duration of the COVID-19 pandemic; healthcare insurer, government, and client payer reimbursement rates for COVID-19 molecular testing; the COVID-19 pandemic’s impact on the U.S. healthcare system and the U.S. economy; and the timing, scope and effectiveness of federal, state and local governmental responses to the COVID-19 pandemic, including the impact of vaccination efforts. We may also be impacted by changes in the severity of the COVID-19 pandemic at different times in the various cities and regions where we operate and offer services. Even as the COVID-19 pandemic continues to moderate and the business and social distancing restrictions continue to ease, we may continue to experience similar effects to our businesses, consolidated results of operations, financial position and cash flows. In the longer term, given the many challenges that hospitals will face, we may have more opportunities to partner with hospitals to help achieve their laboratory strategies, and the COVID-19 pandemic may also be a further catalyst for consolidation in the laboratory testing industry.

Acquisition of the Outreach Laboratory Services Business of Mercy Health

On June 1, 2021, we completed the acquisition of the outreach laboratory services business of Mercy Health, which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma, in an all-cash transaction for $225 million. The acquired business is included in our DIS business.

For further details, see Note 4 to the interim unaudited consolidated financial statements.

Sale of Ownership Interest in Q2 Solutions® ("Q2 Solutions") to IQVIA Holdings, Inc. ("IQVIA")

On April 1, 2021, we sold our 40% ownership interest in Q2 Solutions, our clinical trials central laboratory services joint venture, to IQVIA, our joint venture partner, for $760 million in an all-cash transaction. The sales price is subject to customary post-closing adjustments. Prior to the transaction, we accounted for our minority interest as an equity method investment. As a result of the transaction, during the three months ended June 30, 2021, we recorded a $314 million pre-tax gain in other income (expense), net in the consolidated statement of operations based on the difference between the net sales proceeds and the carrying value of the investment, including $20 million of cumulative translation losses which were previously recorded in accumulated other comprehensive loss. During the three months ended June 30, 2021, we also recorded $55 million of income tax expense related to the gain, consisting of $127 million of current income tax expense, partially offset by $72 million of deferred income tax benefit.

Under a multi-year agreement, we will remain the strategic preferred laboratory provider for Q2 Solutions' clients, providing a range of lab testing capabilities to augment Q2 Solutions' core offerings and extend its industry leading suite of services.

For further details, see Note 5 to the interim unaudited consolidated financial statements.

Accelerated Share Repurchase Agreements ("ASRs")

In April 2021, we entered into ASRs with several financial institutions to repurchase $1.5 billion of our common stock as part of our share repurchase program. Each of the ASRs was structured to permit us to purchase shares immediately with the final purchase price of those shares determined by the volume-weighted average price of our common stock during the repurchase period, less a fixed discount. For the second quarter of 2021, we paid $1.5 billion to the financial institutions and received 9.1 million shares of our common stock, at an initial price of $132.27 per share for a value of $1.2 billion, which represents 80% of the total value of shares to be repurchased under the ASRs.

For further details regarding the ASRs and our repurchases of our common stock, see Note 9 to the interim unaudited consolidated financial statements.

Medicare Sequestration

In April 2021, the suspension of Medicare sequestration, which has resulted in a small benefit to us in the form of higher reimbursement rates for diagnostic testing services performed on behalf of Medicare beneficiaries, was extended through the end of 2021.

Invigorate Program

We are engaged in a multi-year program called Invigorate, which is designed to reduce our cost structure and improve our performance. We currently aim annually to deliver savings of approximately 3% of our costs.

Invigorate has consisted of several flagship programs, with structured plans in each, to drive savings and improve performance across the customer value chain. These flagship programs include: organization excellence; information technology excellence; procurement excellence; field and customer service excellence; lab excellence; and revenue services excellence. In addition to these programs, we have identified key themes to change how we operate including reducing denials and patient price concessions; further digitizing our business; standardization and automation; and optimization initiatives in our lab network and patient service center network. We believe that our efforts to standardize our information technology systems, equipment and data also foster our efforts to strengthen our foundation for growth and support the value creation initiatives of our clinical franchises by enhancing our operational flexibility, empowering and enhancing the customer experience, facilitating the delivery of actionable insights and bolstering our large data platform.

For the six months ended June 30, 2021, we incurred $34 million of pre-tax charges under our Invigorate program primarily consisting of systems conversion and integration costs, all of which result in cash expenditures. Additional restructuring charges may be incurred in future periods as we identify additional opportunities to achieve further cost savings.

Critical Accounting Policies

There have been no significant changes to our critical accounting policies from those disclosed in our 2020 Annual Report on Form 10-K.

Impact of New Accounting Standards

The adoption of new accounting standards, if any, is discussed in Note 2 to the interim unaudited consolidated financial statements.

The impact of recent accounting pronouncements not yet effective on our consolidated financial statements is also discussed in Note 2 to the interim unaudited consolidated financial statements.

Results of Operations

The following tables set forth certain results of operations data for the periods presented:

(dollars in millions, except per share amounts)

Net revenues: Three Months Ended June 30, 2021 2020 $ Change % Change Six Months Ended June 30, 2021 2020 $ Change % Change
DIS business $2,474 $1,764 $710 40.2% $5,117 $3,508 $1,609 45.9%
DS businesses 76 63 13 19.6 153 141 12 8.3
Total net revenues $2,550 $1,827 $723 39.5% $5,270 $3,649 $1,621 44.4%
Operating costs and expenses and other operating income:
Cost of services $1,565 $1,221 $344 28.2% $3,191 $2,491 $700 28.1%
Selling, general and administrative 429 360 69 18.9 836 707 129 18.0
Amortization of intangible assets 25 25 — (0.6) 52 50 2 3.8
Other operating income, net (2) (62) 60 NM (2) (57) 55 NM
Total operating costs and expenses, net $2,017 $1,544 $473 30.6% $4,077 $3,191 $886 27.7%
Operating income $533 $283 $250 88.4% $1,193 $458 $735 160.5%
Other income (expense):
Interest expense, net $(38) $(41) $3 (6.7)% $(76) $(82) $6 (7.4)%
Other income (expense), net 322 13 309 NM 326 (3) 329 NM
Total non-operating income (expense), net $284 $(28) $312 NM $250 $(85) $335 NM
Income tax expense $(177) $(66) $(111) 171.2% $(330) $(92) $(238) 263.1%
Effective income tax rate 21.6% 25.5% 22.9% 24.4%
Equity in earnings of equity method investees, net of taxes $10 $4 $6 178.4% $27 $18 $9 56.2%
Net income attributable to Quest Diagnostics $631 $185 $446 240.5% $1,100 $284 $816 287.0%
Diluted earnings per common share attributable to Quest Diagnostics' common stockholders $4.96 $1.36 $3.60 264.2% $8.38 $2.09 $6.29 300.7%
NM - Not Meaningful

27

The following table sets forth certain results of operations data as a percentage of net revenues for the periods presented:

Net revenues: Three Months Ended June 30, 2021 2020 Six Months Ended June 30, 2021 2020
DIS business 97.0% 96.5% 97.1% 96.1%
DS businesses 3.0 3.5 2.9 3.9
Total net revenues 100.0% 100.0% 100.0% 100.0%
Operating costs and expenses and other operating income:
Cost of services 61.4% 66.8% 60.6% 68.3%
Selling, general and administrative 16.8 19.7 15.8 19.4
Amortization of intangible assets 1.0 1.4 1.0 1.4
Other operating income, net (0.1) (3.4) — (1.6)
Total operating costs and expenses, net 79.1% 84.5% 77.4% 87.5%
Operating income 20.9% 15.5% 22.6% 12.5%

Operating Results

Results for the three months ended June 30, 2021 were affected by certain items that on a net basis increased diluted earnings per share by $1.78 as follows:

  • a pre-tax gain recorded in other income (expense), net of $314 million, or $2.04 per diluted share, on the sale of our 40% ownership interest in Q2 Solutions; and
  • excess tax benefits associated with stock-based compensation arrangements of $5 million, or $0.04 per diluted share, recorded in income tax expense; partially offset by
  • pre-tax amortization expense of $25 million in amortization of intangible assets or $0.15 per diluted share;
  • pre-tax charges of $21 million ($12 million in cost of services and $9 million in selling, general and administrative expenses), or $0.12 per diluted share, primarily associated with workforce reductions, systems conversions and integration incurred in connection with further restructuring and integrating our business; and
  • pre-tax charges of $5 million, or $0.03 per diluted share, associated with donations, contributions and other financial support through Quest for Health Equity, our initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities, recorded in selling, general and administrative expenses.

Results for the six months ended June 30, 2021 were affected by certain items that on a net basis increased diluted earnings per share by $1.42 as follows:

  • a pre-tax gain recorded in other income (expense), net of $314 million, or $1.98 per diluted share, on the sale of our 40% ownership interest in Q2 Solutions; and
  • excess tax benefits associated with stock-based compensation arrangements of $9 million, or $0.07 per diluted share, recorded in income tax expense; partially offset by
  • pre-tax amortization expense of $54 million ($52 million in amortization of intangible assets and $2 million in equity in earnings of equity method investees, net of taxes) or $0.31 per diluted share;
  • pre-tax charges of $38 million ($19 million in cost of services and $19 million in selling, general and administrative expenses), or $0.22 per diluted share, primarily associated with workforce reductions, systems conversions and integration incurred in connection with further restructuring and integrating our business;
  • pre-tax charges of $13 million, or $0.07 per diluted share, including $5 million associated with donations, contributions and other financial support through Quest for Health Equity recorded in selling, general and administrative expenses, and a pre-tax non-cash impairment to the carrying value of an equity method investment, recorded in equity in earnings of equity method investees, net of taxes of $8 million; and
  • pre-tax charges of $4 million in cost of services, or $0.03 per diluted share, representing the impact of certain items resulting from the COVID-19 pandemic including incremental costs incurred to protect the health and safety of our employees and customers.

For both the three and six months ended June 30, 2021, diluted earnings per share benefited from the impact of the ASRs on our weighted average shares outstanding as compared to the prior year periods.

Results for the three months ended June 30, 2020 were affected by certain items that on a net basis reduced diluted earnings per share by $0.06 as follows:

  • pre-tax amortization expense of $28 million ($25 million in amortization of intangible assets and $3 million in equity in earnings of equity method investees, net of taxes) or $0.16 per diluted share; and
  • pre-tax charges of $9 million ($3 million in cost of services and $6 million in selling, general and administrative expenses), or $0.06 per diluted share, representing costs primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business; partially offset by
  • a pre-tax net gain of $26 million (a $62 million gain in other operating income, net and a $3 million gain in equity in earnings of equity method investees, net of taxes, partially offset by $34 million of charges in cost of services and $5 million of charges in selling, general and administrative expenses), or $0.13 per diluted share, representing the impact of certain items resulting from the COVID-19 pandemic including $65 million of income recognized attributable to the receipt of the initial tranche of funds from the government that were appropriated to healthcare providers under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), partially offset by expense associated with a payment to eligible employees to help offset expenses they incurred as a result of COVID-19, certain asset impairment charges, and incremental costs incurred primarily to protect the health and safety of our employees and customers; and
  • excess tax benefits associated with stock-based compensation arrangements of $4 million, or $0.03 per diluted share, recorded in income tax expense.

Results for the six months ended June 30, 2020 were affected by certain items that on a net basis reduced diluted earnings per share by $0.27 as follows:

  • pre-tax amortization expense of $56 million ($50 million in amortization of intangible assets and $6 million in equity in earnings of equity method investees, net of taxes) or $0.31 per diluted share; and
  • pre-tax charges of $25 million ($10 million in cost of services and $15 million in selling, general and administrative expenses), or $0.15 per diluted share, primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business; partially offset by
  • a pre-tax net gain of $17 million (a $57 million gain in other operating income, net and a $3 million gain in equity in earnings of equity method investees, net of taxes, partially offset by $35 million of charges in cost of services, and $8 million of charges in selling, general and administrative expenses), or $0.10 per diluted share, representing the impact of certain items resulting from the COVID-19 pandemic including $65 million of income recognized attributable to the receipt of the initial tranche of funds from the government that were appropriated to healthcare providers under the CARES Act, partially offset by expense associated with a payment to eligible employees to help offset expenses they incurred as a result of COVID-19, certain asset impairment charges, and incremental costs incurred primarily to protect the health and safety of our employees and customers; and
  • excess tax benefits associated with stock-based compensation arrangements of $12 million, or $0.09 per diluted share, recorded in income tax expense.

For both the three and six months ended June 30, 2020, results include $65 million of income recognized attributable to the receipt of the initial tranche of funds from the government that were appropriated to healthcare providers under the CARES Act. During the three months ended September 30, 2020, we reversed the $65 million of income and the funds were returned during the three months ended December 31, 2020.

Net Revenues

Net revenues for the three months ended June 30, 2021 increased by 39.5% compared to the prior year period.

DIS revenues for the three months ended June 30, 2021 increased by 40.2% compared to the prior year period. For the three months ended June 30, 2021:

  • Organic revenue and acquisitions contributed approximately 37.6% and 2.6%, respectively, to DIS revenue growth compared to the prior year period. Organic revenue growth was driven by growth in the base business, partially offset by a decrease in COVID-19 antibody testing.
  • Revenues in the base business (including the impact of recent acquisitions) increased by 66.1% compared to the prior year period, which was negatively impacted as a result of the COVID-19 pandemic. Compared to historical levels in the second quarter of 2019, revenues in the base business, excluding revenue associated with recent acquisitions, increased by 1.4%. Recent agreements associated with our Professional Laboratory Services offerings contributed 2.1% revenue growth compared to 2019.
  • DIS volume increased by 45.2% with organic volume and acquisitions contributing approximately 40.1% and 5.1%, respectively. Organic volume growth was driven by growth in the base business, partially offset by a decrease in volume associated with COVID-19 antibody testing.
  • Testing volume in the base business (including the impact of recent acquisitions) continued to recover and was up 60.7% compared to the prior year period, which was negatively impacted as a result of the COVID-19 pandemic. Compared to historical levels in the second quarter of 2019, testing volume in the base business, excluding volume associated with recent acquisitions, increased 1.9%. Recent agreements associated with our Professional Laboratory Services offerings contributed 5.8% volume growth compared to 2019.
  • Revenue per requisition decreased by 3.6% compared to the prior year period primarily due to growth in our Professional Laboratory Services engagements, which carry a lower revenue per requisition than the average for the remainder of the DIS business, and due to the impact of recent acquisitions.

Net revenues for the six months ended June 30, 2021 increased by 44.4% compared to the prior year period.

DIS revenues for the six months ended June 30, 2021 increased by 45.9% compared to the prior year period. For the six months ended June 30, 2021:

  • Organic revenue and acquisitions contributed approximately 43.0% and 2.9%, respectively, to DIS revenue growth compared to the prior year period. Organic revenue growth was driven by growth in the base business and demand for COVID-19 molecular testing.
  • Revenues in the base business (including the impact of recent acquisitions) increased by 30.2% compared to the prior year period, which was negatively impacted as a result of the COVID-19 pandemic. Compared to historical levels in the first half of 2019, revenues in the base business, excluding revenue associated with recent acquisitions, decreased by 0.7%. Recent agreements associated with our Professional Laboratory Services offerings contributed 2.3% revenue growth compared to 2019.
  • DIS volume increased by 34.7% with organic volume and acquisitions contributing approximately 30.0% and 4.7%, respectively. Organic volume growth was driven by growth in the base business and, to a lesser extent, demand for COVID-19 molecular testing.
  • Testing volume in the base business (including the impact of recent acquisitions) continued to recover and was up 28.0% compared to the prior year period, which was negatively impacted as a result of the COVID-19 pandemic. Compared to historical levels in the first half of 2019, testing volume in the base business, excluding volume associated with recent acquisitions, decreased by 0.4%. Recent agreements associated with our Professional Laboratory Services offerings contributed 5.5% volume growth compared to 2019.
  • Revenue per requisition increased by 8.1% compared to the prior year period driven in large part by COVID-19 molecular testing, partially offset by growth in our Professional Laboratory Services engagements, which carry a lower revenue per requisition than the average for the remainder of the DIS business.

Cost of Services

Cost of services consists principally of costs for obtaining, transporting and testing specimens as well as facility costs used for the delivery of our services.

For the three months ended June 30, 2021, cost of services increased by $344 million compared to the prior year period. The increase was primarily driven by higher variable expenses related to increased testing volumes and, to a lesser extent, additional operating costs associated with our acquisitions, partially offset by higher incremental costs incurred in the prior year period related to the COVID-19 pandemic including expense associated with a payment to eligible employees to help offset expenses they incurred as a result of COVID-19.

For the six months ended June 30, 2021, cost of services increased by $700 million compared to the prior year period. The increase was primarily driven by higher variable expenses related to increased testing volumes as well as test mix and a higher supply cost associated with COVID-19 testing, and, to a lesser extent, additional operating costs associated with our acquisitions.

Selling, General and Administrative Expenses ("SG&A")

SG&A consist principally of the costs associated with our sales and marketing efforts, billing operations, credit loss expense and general management and administrative support as well as administrative facility costs.

SG&A increased by $69 million for the three months ended June 30, 2021, compared to the prior year period, primarily driven by higher variable expenses to support our increase in testing volumes as well as higher performance-based compensation.

SG&A increased by $129 million for the six months ended June 30, 2021, compared to the prior year period, primarily driven by higher variable expenses to support our increase in testing volumes, higher performance-based compensation, and higher costs associated with changes in the value of our deferred compensation obligations.

The change in the value of our deferred compensation obligations is largely offset by gains or losses due to the changes in the value of the associated investments, which are recorded in other income (expense), net. For further details regarding our deferred compensation plans, see Note 17 to the audited consolidated financial statements in our 2020 Annual Report on Form 10-K.

Amortization Expense

For the six months ended June 30, 2021, amortization expense increased by $2 million compared to the prior year period as a result of recent acquisitions.

Other Operating Income, Net

Other operating income, net includes miscellaneous income and expense items and other charges related to operating activities.

For both the three and six months ended June 30, 2020, other operating income, net primarily represents $65 million of income recognized attributable to the receipt of the initial tranche of funds from the government that were appropriated to healthcare providers under the CARES Act. During the three months ended September 30, 2020, we reversed the $65 million of income and the funds were returned during the three months ended December 31, 2020.

Interest Expense, Net

Interest expense, net decreased for the three months ended June 30, 2021 compared to the prior year period, primarily due to lower average outstanding indebtedness.

Interest expense, net decreased for the six months ended June 30, 2021 compared to the prior year period, primarily driven by lower interest rates due to recent refinancing transactions, including the termination of our interest rate swap agreements in April 2020, which resulted in a deferred gain that is being amortized as a reduction of interest expense, net over the remaining term of the associated debt, combined with lower average outstanding indebtedness.

Other Income (Expense), Net

Other income (expense), net represents miscellaneous income and expense items related to non-operating activities, such as gains and losses associated with investments and other non-operating assets.

For the three months ended June 30, 2021, other income (expense), net increased by $309 million compared to the prior year period primarily due to a $314 million pre-tax gain on the sale of our 40% ownership interest in Q2 Solutions, our clinical trials central laboratory services joint venture, to IQVIA, our joint venture partner, partially offset by changes in the value of investments associated with our deferred compensation plans.

For the six months ended June 30, 2021, other income (expense), net increased by $329 million compared to the prior year period primarily due to the pre-tax gain on the sale of our 40% ownership interest in Q2 Solutions and, to a lesser extent, changes in the value of investments associated with our deferred compensation plans.

Income Tax Expense

Income tax expense for the three months ended June 30, 2021 and 2020 was $177 million and $66 million, respectively. The increase in income tax expense for the three months ended June 30, 2021 compared to the prior year period was primarily driven by an increase in income before income taxes and equity in earnings of equity method investees.

For the three months ended June 30, 2021 and 2020, the effective income tax rate was 21.6% and 25.5%, respectively. For the three months ended June 30, 2021, the effective income tax rate benefited from a lower effective income tax rate, 17.6%, on the gain on the sale of our 40% ownership interest in Q2 Solutions. In addition, the effective income tax rate benefited from $5 million and $4 million of excess tax benefits associated with stock-based compensation arrangements for the three months ended June 30, 2021 and 2020, respectively.

Income tax expense for the six months ended June 30, 2021 and 2020 was $330 million and $92 million, respectively. The increase in income tax expense for the six months ended June 30, 2021 compared to the prior year period was primarily driven by an increase in income before income taxes and equity in earnings of equity method investees.

For the six months ended June 30, 2021 and 2020, the effective income tax rate was 22.9% and 24.4%, respectively. For the six months ended June 30, 2021, the effective income tax rate benefited from a lower effective income tax rate, 17.6%, on the gain on the sale of our 40% ownership interest in Q2 Solutions. In addition, the effective income tax rate benefited from $9 million and $12 million of excess tax benefits associated with stock-based compensation arrangements for the six months ended June 30, 2021 and 2020, respectively.

Equity in Earnings of Equity Method Investees, Net of Taxes

Equity in earnings of equity method investees, net of taxes increased for the three months ended June 30, 2021 by $6 million compared to the prior year period primarily due to recovery in the base business (which excludes COVID-19 testing) of the investees, which was negatively impacted in 2020 as a result of the COVID-19 pandemic.

Equity in earnings of equity method investees, net of taxes increased for the six months ended June 30, 2021 by $9 million compared to the prior year period primarily due to the demand for COVID-19 testing services, partially offset by an $8 million non-cash impairment to the carrying value of an equity method investment.

Quantitative and Qualitative Disclosures About Market Risk

We address our exposure to market risks, principally the risk of changes in interest rates, through a controlled program of risk management that includes the use of derivative financial instruments. We do not hold or issue derivative financial instruments for speculative purposes. We seek to mitigate the variability in cash outflows that result from changes in interest rates by maintaining a balanced mix of fixed-rate and variable-rate debt obligations. In order to achieve this objective, we have historically entered into interest rate swap agreements. Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements are recognized as an adjustment to interest expense, net. We believe that our exposures to foreign exchange impacts and changes in commodity prices are not material to our consolidated results of operations, financial position or cash flows.

As of June 30, 2021 and December 31, 2020, the fair value of our debt was estimated at approximately $4.5 billion and $4.6 billion, respectively, principally using quoted prices in active markets and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. As of June 30, 2021 and December 31, 2020, the estimated fair value exceeded the carrying value of the debt by $463 million and $597 million, respectively. A hypothetical 10% increase in interest rates (representing 21 basis points as of June 30, 2021 and 17 basis points as of December 31, 2020) would potentially reduce the estimated fair value of our debt by approximately $87 million and $82 million as of June 30, 2021 and December 31, 2020, respectively.

Borrowings under our secured receivables credit facility and our senior unsecured revolving credit facility are subject to variable interest rates. Interest on our secured receivables credit facility is based on either commercial paper rates for highly rated issuers, or LIBOR, plus a spread. As of June 30, 2021, interest on our senior unsecured revolving credit facility is based on certain published rates plus an applicable margin based on changes in our public debt ratings and our leverage ratio. As such, our borrowing cost under this credit arrangement is subject to fluctuations in interest rates, our leverage ratio and changes in our public debt ratings. As of June 30, 2021, the borrowing rates under these debt instruments were: for our secured receivables credit facility, commercial paper rates for highly-rated issuers or LIBOR, plus a spread of 0.825% to 0.950%; and for our senior unsecured revolving credit facility, LIBOR plus 1.125%. As of June 30, 2021, there were no borrowings outstanding under either our $600 million secured receivables credit facility or our $750 million senior unsecured revolving credit facility.

A hypothetical 10% change to the variable rate component of our variable rate indebtedness would not materially change our annual interest expense.

For further details regarding our outstanding debt, see Note 13 to the audited consolidated financial statements included in our 2020 Annual Report on Form 10-K. For details regarding our financial instruments and hedging activities, see Note 8 to the interim unaudited consolidated financial statements and Note 15 to the audited consolidated financial statements included in our 2020 Annual Report on Form 10-K.

Risk Associated with Investment Portfolio

Our investment portfolio primarily includes equity investments comprised mostly of strategic holdings in privately and publicly held companies. These securities are exposed to price fluctuations and are generally concentrated in the life sciences and healthcare industries. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value with changes in fair value recognized in net income. Equity investments that do not have readily determinable fair values are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes. We regularly evaluate these equity investments to determine if there are any indicators that the investment is impaired. The carrying value of our equity investments that do not have readily determinable fair values was $26 million as of June 30, 2021.

We do not hedge our equity price risk. The impact of an adverse movement in equity prices on our holdings in privately held companies cannot be easily quantified, as our ability to realize returns on investments depends on, among other things, the enterprises’ ability to raise additional capital or derive cash inflows from continuing operations or through liquidity events such as initial public offerings, mergers or private sales.

In conjunction with the preparation of our June 30, 2021 financial statements, we considered whether the carrying values of our investments were impaired and concluded that no such impairment existed.

Liquidity and Capital Resources

(dollars in millions)

Six Months Ended June 30, 2021 2020 Change
Net cash provided by operating activities $1,191 $602 $589
Net cash provided by (used in) investing activities 344 (411) 755
Net cash used in financing activities (2,133) (395) (1,738)
Net change in cash and cash equivalents and restricted cash $(598) $(204) $(394)

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly-liquid short-term investments. Cash and cash equivalents as of June 30, 2021 totaled $560 million, compared to $1,158 million as of December 31, 2020.

As of June 30, 2021, approximately 7% of our $560 million of consolidated cash and cash equivalents were held outside of the United States.

Cash Flows from Operating Activities

Net cash provided by operating activities for the six months ended June 30, 2021 and 2020 was $1,191 million and $602 million, respectively. The $589 million increase in net cash provided by operating activities for the six months ended June 30, 2021, compared to the prior year period was primarily a result of:

  • higher operating income in 2021 as compared to 2020; and, to a lesser extent,
  • the timing of movements in our working capital accounts; partially offset by
  • a $315 million increase in income tax payments due to higher operating income in 2021 as compared to 2020 combined with lower payments in the 2020 period as a result of the extension of various payment deadlines into the second half of 2020;
  • higher performance-based compensation payments in 2021 compared to 2020, and
  • $65 million in proceeds in the 2020 period that we received from the initial tranche of funds that were appropriated to healthcare providers under the CARES Act, which funds were returned during the fourth quarter of 2020.

Days sales outstanding ("DSO"), a measure of billing and collection efficiency, was 46 days as of June 30, 2021, 46 days as of December 31, 2020 and 44 days as of June 30, 2020. Recent changes in our DSO is partially due to fluctuations in our monthly revenue due to the impact of the COVID-19 pandemic.

Cash Flows from Investing Activities

Net cash provided by (used in) investing activities for the six months ended June 30, 2021 and 2020 was $344 million and $(411) million, respectively. This $755 million change in cash provided by (used in) investing activities for the six months ended June 30, 2021, compared to the prior year period was primarily a result of net cash proceeds received from the sale of our 40% ownership interest in Q2 Solutions.

Cash Flows from Financing Activities

Net cash used in financing activities for the six months ended June 30, 2021 and 2020 was $2,133 million and $395 million, respectively. This $1,738 million increase in cash used in financing activities for the six months ended June 30, 2021, compared to the prior year period was primarily a result of:

  • a $1,835 million increase in repurchases of our common stock (see "Share Repurchase Program" for further details); and, to a lesser extent,
  • a $49 million decrease in proceeds from the exercise of stock options, which was a result of a decrease in the volume of stock options exercised compared to the prior year; and
  • a $43 million increase in distributions to noncontrolling interest partners; partially offset by
  • $252 million of net debt repayments (repayments of debt less proceeds from borrowings) in 2020 compared to $1 million of net debt repayments in 2021.

During the six months ended June 30, 2021, there were no borrowings or repayments under our secured receivables credit facility or senior unsecured revolving credit facility.

During the six months ended June 30, 2020, we completed the issuance of the 2.80% senior notes due June 2031. Additionally, during the six months ended June 30, 2020, we redeemed in full the outstanding indebtedness under our senior notes due January 2020 and senior notes due March 2020 using proceeds from the issuance, in December 2019, of the 2.95% senior notes due June 2030, along with cash on hand. During the six months ended June 30, 2020, we borrowed $100 million under our secured receivables credit facility and $100 million under our senior unsecured revolving credit facility, which were repaid prior to June 30, 2020.

Dividend Program

During the first and second quarters of 2021, our Board of Directors declared a quarterly cash dividend of $0.62 per common share. During each of the four quarters of 2020, our Board of Directors declared a quarterly cash dividend of $0.56 per common share.

Share Repurchase Program

In each of February and March 2021, our Board of Directors increased the size of our share repurchase program by $1 billion. As of June 30, 2021, $1.3 billion remained available under our share repurchase authorization. The share repurchase authorization has no set expiration or termination date.

Share Repurchases

For the six months ended June 30, 2021, we repurchased 12.5 million shares of our common stock for $1.6 billion, including 9.1 million shares repurchased under ASRs. See "Second Quarter Highlights" above for further details.

For the six months ended June 30, 2020, we repurchased 0.7 million shares of our common stock for $75 million.

Equity Method Investees

Our equity method investees primarily consist of a diagnostic information services joint venture and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry. Such investees are accounted for under the equity method of accounting. Our investment in equity method investees is less than 5% of our consolidated total assets. Our proportionate share of income before income taxes associated with our equity method investees is less than 5% of our consolidated income before income taxes and equity in earnings of equity method investees. We have no material unconditional obligations or guarantees to, or in support of, our equity method investees and their operations.

In conjunction with the preparation of our June 30, 2021 financial statements, we considered whether the carrying values of our equity method investments were impaired and, during the six months ended June 30, 2021, we recorded an $8 million impairment charge for one of the investments.

For further details regarding related party transactions with our equity method investees, see Note 20 to the audited consolidated financial statements in our 2020 Annual Report on Form 10-K.

Requirements and Capital Resources

We estimate that we will invest approximately $400 million during 2021 for capital expenditures, to support and grow our existing operations, principally related to investments in information technology, laboratory equipment and facilities, including COVID-19 testing equipment and completion of our new multi-year laboratory construction in New Jersey, and investments in our advanced diagnostics and consumer growth strategies.

Together with the Quest Diagnostics Foundation, during 2020 we launched a multi-year initiative to reduce health disparities in underserved communities, including those impacted by the COVID-19 pandemic. As part of this initiative, we plan to offer testing services and fund a range of initiatives estimated to total more than $100 million aimed at improving access to testing and awareness of the value of diagnostic insights in managing overall health, a significant portion of which will occur in 2021.

As of June 30, 2021, we had $1.3 billion of borrowing capacity available under our existing credit facilities, including $530 million available under our secured receivables credit facility and $750 million available under our senior unsecured revolving credit facility. There were no borrowings under these credit facilities as of June 30, 2021. In support of our risk management program, $70 million in letters of credit under the secured receivables credit facility were outstanding as of June 30, 2021. The secured receivables credit facility includes a $250 million loan commitment which matures in October 2021, and a $250 million loan commitment and a $100 million letter of credit facility which mature in October 2022. The senior unsecured revolving credit facility matures in March 2023. For further details regarding the credit facilities, see Note 13 to the audited consolidated financial statements in our 2020 Annual Report on Form 10-K.

Our secured receivables credit facility is subject to customary affirmative and negative covenants, and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. Our senior unsecured revolving credit facility is also subject to certain financial covenants and limitations on indebtedness. As of June 30, 2021, we were in compliance with all such applicable financial covenants.

We believe that our cash and cash equivalents and cash from operations, together with our borrowing capacity under our credit facilities, will provide sufficient financial flexibility to fund seasonal and other working capital requirements, capital expenditures, debt service requirements and other obligations, cash dividends on common shares, share repurchases and additional growth opportunities for the foreseeable future. However, should it become necessary, we believe that our credit profile should provide us with access to additional financing in order to fund normal business operations, make interest payments, fund growth opportunities and satisfy upcoming debt maturities.

Forward-Looking Statements

Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in our most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

Controls and procedures

As filed, 788 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Management, including our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

During the second quarter of 2021, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-04-01 to 2021-06-30$2.55bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2021-01-01 to 2021-06-30$5.27bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-04-01 to 2021-06-30$1.56bnus-gaap:CostOfRevenue
Cost of revenue6 months2021-01-01 to 2021-06-30$3.19bnus-gaap:CostOfRevenue
Selling, general and administrative3 months2021-04-01 to 2021-06-30$429.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2021-01-01 to 2021-06-30$836.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-04-01 to 2021-06-30$533.0mus-gaap:OperatingIncomeLoss
Operating income6 months2021-01-01 to 2021-06-30$1.19bnus-gaap:OperatingIncomeLoss
Interest expense3 months2021-04-01 to 2021-06-30$38.0mus-gaap:InterestExpense
Interest expense6 months2021-01-01 to 2021-06-30$76.0mus-gaap:InterestExpense
Income tax3 months2021-04-01 to 2021-06-30$177.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2021-01-01 to 2021-06-30$330.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-01 to 2021-06-30$631.0mus-gaap:NetIncomeLoss
Net income6 months2021-01-01 to 2021-06-30$1.10bnus-gaap:NetIncomeLoss
Diluted EPS3 months2021-04-01 to 2021-06-30$4.96us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2021-01-01 to 2021-06-30$8.38us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-04-01 to 2021-06-30$5.05us-gaap:EarningsPerShareBasic
Basic EPS6 months2021-01-01 to 2021-06-30$8.52us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-04-01 to 2021-06-30127,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2021-01-01 to 2021-06-30131,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2021-01-01 to 2021-06-30$1.19bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2021-01-01 to 2021-06-30$170.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2021-01-01 to 2021-06-30$156.0mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases6 months2021-01-01 to 2021-06-30$1.91bnus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-06-30$560.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-06-30$2.15bnus-gaap:AssetsCurrent
Total assetsAt period end2021-06-30$12.86bnus-gaap:Assets
Current liabilitiesAt period end2021-06-30$1.55bnus-gaap:LiabilitiesCurrent
Current portion of debtAt period end2021-06-30$2.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2021-06-30$5.90bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001022079-21-000111. Last ingested by Listed: Nov 13, 2026, 17:16 ET. Listed shows no prices and gives no investment advice.